NewsletterSage Therapeutics Starting Phase 2 Study of SAGE-547 (6-hour infusion drug) for Treating Tinnitus
NewsRespireRx Pharmaceuticals Highlights Potential Use of GABAkine Neuromodulators for Treatment of Tinnitus
NewsOtonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313
NewsAnti-Tinnitus Effects of “Prism Adaptation” Glasses: Researchers in France to Begin Major Study Next Month (August 2021)
NewsThanos Tzounopoulos explains the current state of tinnitus drug development research (and the crucial missing piece)
NewsKetamine + HD-tIPNS for tinnitus: Professor Dirk De Ridder investigates effects of new “drug/device combo” therapy
NewsResearchers evaluating the effects of bitter almond oil and cinnarizine on chronic tinnitus severity
NewsOtonomy Now Recruiting Participants for Phase 2 Study of OTO-313 in Tinnitus [Update: New Locations Added]
NewsAmerican Tinnitus Association Seeking Tinnitus Research Proposals… “that may contribute to scientific understanding of tinnitus, breakthroughs in treatments, and possible cures”
NewsOtolith Labs Initiates Clinical Trial of OtoBand Device as a Treatment to Reduce Perceived Loudness of Tinnitus
NewsFrequency Therapeutics Announces Publication of Phase 1/2 Data Showing Hearing Improvements in Patients Receiving FX-322
NewsBREAKTHROUGH: NAC/HPN-07, also known as the Hough Ear Institute’s NHPN-1010, significantly reduced the incidence of tinnitus, study finds…
NewsAmerican Tinnitus Association Receives $2.7 Million Donation – Money Will Help Fund Strategic Long-Term Tinnitus Research
NewsBritish Tinnitus Association awards £125k grant for research that could predict who will develop tinnitus
NewsIn Case You Missed It: Tinnitus Hub Director Hazel Goedhart gives us the cold, hard, unbiased facts about Lenire…
NewsNew FX-322 clinical trial for severe hearing loss includes tinnitus assessment as secondary outcome measure
NewsNeuromod Successfully Closes $12.4 Million Series B Financing for Tinnitus Treatment Device Lenire®
NewsNew Treatment Alleviates Ringing in the Ears: A noninvasive device [Lenire] designed to rewire brain circuits reduced symptoms of tinnitus in a large clinical trial
NewsFrequency Therapeutics Completes Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss
NewsFrequency Therapeutics Presents Results Demonstrating Sustained Improvement in Hearing Loss Patients Treated with FX-322
NewsDr. Will Sedley discusses role of “predictive brain processing” in tinnitus – via Tinnitus Talk [PDF]
NewsCarl LeBel (Chief Development Officer at Frequency Therapeutics) talks FX-322 in latest interview – via Tinnitus Talk [PDF]
NewsUpdate on new tinnitus drug (GW-201) from NEOMED researcher Jianxin Bao and Gateway Biotechnology
NewsOtonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus
NewsOtonomy Provides Update on Clinical Trials: Results from Phase 1/2 trial of OTO-313 for tinnitus expected in July 2020
NewsCongressman Announces National Institute on Deafness and Other Communications Disorders Grant for Tinnitus Prevention and Treatment
NewsFrequency Therapeutics Shares Clinical Data From Exploratory Study Confirming Delivery of FX-322 to the Cochlea – Top-Line Results Show Consistent Drug Entry in All Patients
NewsFAU researchers use computer-based ‘stochastic resonance’ model of tinnitus as a basis for developing new treatment strategies
NewsUpdated list of hearing loss treatment news and research available at HearingLossTreatmentReport.com
NewsTinnitus Research Spotlight: A unified explanation of tinnitus development based on the Stochastic Resonance (SR) model of auditory perception
NewsNO COVID-19 SLOWDOWN: Frequency Therapeutics Adds Another Recruitment Site for FX-322 Phase 2a Study (HearingLossTreatmentReport.com)
NewsStudy findings demonstrate that Lenire (Neuromod) for tinnitus “provides safe, fast-acting (within 6 weeks) and reproducible therapeutic effects that can last at least 12 months.”
NewsResaphene Suisse AG: Charité Ethics Committee in Berlin Approves Study on Tinniwell Tinnitus Therapy
NewsCognosetta, Inc receives funding from NIH to test a novel therapeutic for treating tinnitus (BMS-191011)
NewsAuris Medical Receives “Intention to Grant” notice from European Patent Office for New Oral NKCC1 inhibitor Treatment for Tinnitus
NewsZilentin: Auris Medical Announces Formation of New Subsidiary for Development Projects in Tinnitus and Hearing Loss
NewsAmerican Tinnitus Association and British Tinnitus Association Partner to Spark Innovations in Tinnitus Treatments and Advance Global Discussion About Potential Tinnitus Breakthroughs
NewsFrequency Therapeutics CEO: “We have opened all U.S. sites for our Phase 2a study of FX-322 and remain on track to report top-line data in the second half of next year.”
NewsRESEARCH: Experimental procedure enables suppression of auditory cortex alpha activity in patients with chronic tinnitus
NewsFrequency Therapeutics Begins Recruiting for Phase 2 Study of FX-322 in Patients with Sensorineural Hearing Loss
NewsNeuromod (Lenire) Clinical Trial Data “Locked” Until Fall 2020? Study Results “Delayed” Until 2021?
NewsNeuromod Successfully Closes €8 Million Capital Raise: proceeds will be used to accelerate ongoing commercialization of Lenire® tinnitus treatment device
NewsAuris Medical Receives FDA and EMA Guidance for Keyzilen® (AM-101) Late-Stage Clinical Development Program
